Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Expression System:
HEK293
Purity:
> 95% as determined by Bis-Tris PAGE,> 95% as determined by HPLC
Form:
Lyophilized
Sequence:
Ala27-Arg191
Target:
VEGF165
Human VEGF165 on Bis-Tris PAGE under reduced condition and Non reduced (N) condition. The purity is greater than 95%.
Immobilized Human VEGF165, No Tag at 5ug/ml (100ul/well) on the plate. Dose response curve for Human VEGF R2, HisTag (Cat. VGF-HM1R2) with the EC50 of 0.35ug/ml determined by ELISA.
Immobilized Human VEGF165 at 1ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Human VEGFR1, His Tag with the EC50 of 46.4ng/ml determined by ELISA.
Measured by a reporter gene assay using HEK293T-KDR-NFAT Cell line. The ED50-for this effect is < 10 ng/mL (QC Test).
Immobilized Human VEGF165, No Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 2.7ng/ml determined by ELISA.
Serial dilutions of Anti-VEGF165 Antibody were added into Human VEGF165, No Tag: Biotinylated Human VEGF R2, His Avi Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.30ug/ml.
The purity of Human VEGF165 is greater than 95% as determined by SEC-HPLC.
* VAT and and shipping costs not included. Errors and price changes excepted